JP2007501683A5 - - Google Patents

Download PDF

Info

Publication number
JP2007501683A5
JP2007501683A5 JP2006532906A JP2006532906A JP2007501683A5 JP 2007501683 A5 JP2007501683 A5 JP 2007501683A5 JP 2006532906 A JP2006532906 A JP 2006532906A JP 2006532906 A JP2006532906 A JP 2006532906A JP 2007501683 A5 JP2007501683 A5 JP 2007501683A5
Authority
JP
Japan
Prior art keywords
present
sterilization
nanoparticle
active agent
active agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006532906A
Other languages
English (en)
Other versions
JP2007501683A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/014528 external-priority patent/WO2004105809A1/en
Publication of JP2007501683A publication Critical patent/JP2007501683A/ja
Publication of JP2007501683A5 publication Critical patent/JP2007501683A5/ja
Pending legal-status Critical Current

Links

Description

発明の概要
本発明は、1種または複数のナノ粒子活性物質の分散体をγ線照射によりうまく滅菌することができる（最終滅菌を含む）という驚くべき発見に関する。滅菌後、この分散体中に存在する活性物質のナノ粒子の粒径は、当初のナノ粒子活性物質粒径と実質的に類似している。
発明の詳細な説明
本発明は、1種または複数のナノ粒子活性物質の分散体の最終滅菌を含む新規の滅菌方法の驚くべきかつ予想外の発見に関する。当技術分野において公知の方法に従い調製された、1種または複数のナノ粒子活性物質の分散体は、活性物質ナノ粒子を滅菌するのに十分な期間、γ線照射により照射される。
実施例において得られた結果は、本発明の方法の適用により、無菌の注射用ナノ粒子製剤が得られることを例示している。粒径およびアッセイについて得られた結果に加え、微生物学上のおよび無菌性に関する結果は、本発明の方法を使用することにより、非経口投与に適している最終滅菌されたナノ粒子製剤が得られることを示している。
JP2006532906A 2003-05-22 2004-05-24 γ線照射によるナノ粒子活性物質分散体の滅菌法 Pending JP2007501683A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47243403P 2003-05-22 2003-05-22
PCT/US2004/014528 WO2004105809A1 (en) 2003-05-22 2004-05-24 Sterilization of dispersions of nanoparticulate active agents with gamma radiation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011179337A Division JP2012030078A (ja) 2003-05-22 2011-08-19 γ線照射によるナノ粒子活性物質分散体の滅菌法

Publications (2)

Publication Number Publication Date
JP2007501683A JP2007501683A (ja) 2007-02-01
JP2007501683A5 true JP2007501683A5 (ja) 2010-05-27

Family

ID=33490505

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006532906A Pending JP2007501683A (ja) 2003-05-22 2004-05-24 γ線照射によるナノ粒子活性物質分散体の滅菌法
JP2011179337A Pending JP2012030078A (ja) 2003-05-22 2011-08-19 γ線照射によるナノ粒子活性物質分散体の滅菌法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011179337A Pending JP2012030078A (ja) 2003-05-22 2011-08-19 γ線照射によるナノ粒子活性物質分散体の滅菌法

Country Status (5)

Country Link
US (1) US7842232B2 (ja)
EP (1) EP1626742A1 (ja)
JP (2) JP2007501683A (ja)
CA (1) CA2523035C (ja)
WO (1) WO2004105809A1 (ja)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7758890B2 (en) 2001-06-23 2010-07-20 Lyotropic Therapeutics, Inc. Treatment using dantrolene
FR2898273B1 (fr) * 2006-03-07 2013-11-08 Merck Generiques Procede de sterilisation par chauffage par voie seche d'une poudre comprenant un glucocorticosteroide
WO2011146583A2 (en) 2010-05-19 2011-11-24 Elan Pharma International Limited Nanoparticulate cinacalcet formulations
TWI577377B (zh) 2010-09-16 2017-04-11 Ｖｉｉｖ醫療保健公司 醫藥組合物
GB201020236D0 (en) 2010-11-30 2011-01-12 Convatec Technologies Inc A composition for detecting biofilms on viable tissues
US9232790B2 (en) 2011-08-02 2016-01-12 Kimberly-Clark Worldwide, Inc. Antimicrobial cleansing compositions
US11596599B2 (en) 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
EP2844227B1 (en) 2012-05-03 2020-11-18 Kala Pharmaceuticals, Inc. Pharmaceutical nanoparticles showing improved mucosal transport
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
CA2871778C (en) 2012-05-03 2022-09-13 Kala Pharmaceuticals, Inc. Pharmaceutical nanoparticles showing improved mucosal transport
CA2900652C (en) 2013-02-15 2021-05-04 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
BR112015020139A2 (pt) 2013-02-20 2017-07-18 Kala Pharmaceuticals Inc compostos terapêuticos e usos dos mesmos
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
US9458169B2 (en) 2013-11-01 2016-10-04 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
EP2886121A1 (de) * 2013-12-23 2015-06-24 Dr. Falk Pharma Gmbh Wässrige Suspension enthaltend Budesonid zur Behandlung von entzündlichen Veränderungen des Ösophagus
US11260020B2 (en) 2014-04-30 2022-03-01 Kimberly-Clark Worldwide, Inc. Topical compositions and methods for reducing oxidative stress
KR102246477B1 (ko) 2014-04-30 2021-04-30 킴벌리-클라크 월드와이드, 인크. 피부 노화의 징후를 감소시키는 방법
BR112016023571B1 (pt) 2014-04-30 2020-12-01 Kimberly-Clark Worldwide, Inc. métodos para reduzir os sinais de envelhecimento da pele em um indivíduo, para aumentar a adipogênese da face e do corpo de um indivíduo e para aumentar a lipogênese da face e do corpo de um indivíduo
AU2014392626B2 (en) 2014-04-30 2020-07-02 Kimberly-Clark Worldwide, Inc. Topical compositions for stimulating adipogenesis and lipogenesis to reduce the signs of skin aging
CN108135838A (zh) 2015-10-16 2018-06-08 马瑞纳斯制药公司 包含纳米粒的可注射神经类固醇制剂
WO2018048750A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
CA3036065A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US10253036B2 (en) 2016-09-08 2019-04-09 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
BR112020003956A2 (pt) * 2017-06-30 2021-08-03 Otomagnetics, Inc. nanopartículas magnéticas para entrega direcionada, composição e método de uso
CN114728012A (zh) 2019-08-05 2022-07-08 马瑞纳斯制药公司 用于治疗癫痫持续状态的加奈索酮
CA3184868A1 (en) 2020-07-09 2022-01-13 Rene Holm Long-acting formulations
CA3182425A1 (en) 2020-07-09 2022-01-13 Rene Holm Long-acting formulations
WO2024068699A1 (en) 2022-09-28 2024-04-04 Janssen Pharmaceutica Nv Long-acting formulations
WO2024068693A1 (en) 2022-09-28 2024-04-04 Janssen Pharmaceutica Nv Long-acting formulations
CN115844821B (zh) * 2023-01-03 2024-05-17 江苏知原药业股份有限公司 一种地奈德纳米晶混悬液、制备方法及其应用

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2403078A1 (fr) 1977-09-19 1979-04-13 Lafon Labor Nouveau procede de preparation de formes pharmaceutiques, cosmetiques ou de diagnostic
US4330626A (en) 1980-03-19 1982-05-18 The Enzyme Center, Inc. Method of preparing high-activity, low-bacteria, urease enzyme
US4826689A (en) 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
US4783484A (en) 1984-10-05 1988-11-08 University Of Rochester Particulate composition and use thereof as antimicrobial agent
GB8817240D0 (en) 1988-07-20 1988-08-24 Univ Salford Business Services Sterilising methods
FR2634376B1 (fr) 1988-07-21 1992-04-17 Farmalyoc Nouvelle forme unitaire, solide et poreuse comprenant des microparticules et/ou des nanoparticules, ainsi que sa preparation
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
AU642066B2 (en) 1991-01-25 1993-10-07 Nanosystems L.L.C. X-ray contrast compositions useful in medical imaging
US5552160A (en) 1991-01-25 1996-09-03 Nanosystems L.L.C. Surface modified NSAID nanoparticles
WO1993000933A1 (en) 1991-07-05 1993-01-21 University Of Rochester Ultrasmall non-aggregated porous particles entrapping gas-bubbles
JP3320430B2 (ja) 1991-07-10 2002-09-03 日本原子力研究所 放射線滅菌による無菌リン脂質、リン脂質水分散液又はリポソーム水分散液の製造法
NZ248813A (en) 1992-11-25 1995-06-27 Eastman Kodak Co Polymeric grinding media used in grinding pharmaceutical substances
US5349957A (en) 1992-12-02 1994-09-27 Sterling Winthrop Inc. Preparation and magnetic properties of very small magnetite-dextran particles
US5298262A (en) * 1992-12-04 1994-03-29 Sterling Winthrop Inc. Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
US5346702A (en) 1992-12-04 1994-09-13 Sterling Winthrop Inc. Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
US5302401A (en) 1992-12-09 1994-04-12 Sterling Winthrop Inc. Method to reduce particle size growth during lyophilization
US5340564A (en) 1992-12-10 1994-08-23 Sterling Winthrop Inc. Formulations comprising olin 10-G to prevent particle aggregation and increase stability
US5336507A (en) 1992-12-11 1994-08-09 Sterling Winthrop Inc. Use of charged phospholipids to reduce nanoparticle aggregation
US5429824A (en) 1992-12-15 1995-07-04 Eastman Kodak Company Use of tyloxapole as a nanoparticle stabilizer and dispersant
US5352459A (en) 1992-12-16 1994-10-04 Sterling Winthrop Inc. Use of purified surface modifiers to prevent particle aggregation during sterilization
US5326552A (en) 1992-12-17 1994-07-05 Sterling Winthrop Inc. Formulations for nanoparticulate x-ray blood pool contrast agents using high molecular weight nonionic surfactants
US5401492A (en) 1992-12-17 1995-03-28 Sterling Winthrop, Inc. Water insoluble non-magnetic manganese particles as magnetic resonance contract enhancement agents
US5264610A (en) 1993-03-29 1993-11-23 Sterling Winthrop Inc. Iodinated aromatic propanedioates
US5716981A (en) 1993-07-19 1998-02-10 Angiogenesis Technologies, Inc. Anti-angiogenic compositions and methods of use
US5362442A (en) 1993-07-22 1994-11-08 2920913 Canada Inc. Method for sterilizing products with gamma radiation
CA2128821A1 (en) 1993-07-27 1995-01-28 Dilip J. Gole Freeze-dried pharmaceutical dosage form and process for separation thereof
GB9410222D0 (en) 1994-05-21 1994-07-06 Glaxo Wellcome Australia Ltd Medicaments
TW384224B (en) 1994-05-25 2000-03-11 Nano Sys Llc Method of preparing submicron particles of a therapeutic or diagnostic agent
US5718388A (en) 1994-05-25 1998-02-17 Eastman Kodak Continuous method of grinding pharmaceutical substances
US5525328A (en) 1994-06-24 1996-06-11 Nanosystems L.L.C. Nanoparticulate diagnostic diatrizoxy ester X-ray contrast agents for blood pool and lymphatic system imaging
US5587143A (en) 1994-06-28 1996-12-24 Nanosystems L.L.C. Butylene oxide-ethylene oxide block copolymer surfactants as stabilizer coatings for nanoparticle compositions
DE4440337A1 (de) 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
DE4446891A1 (de) 1994-12-27 1996-07-04 Falk Pharma Gmbh Stabile wäßrige Budesonid-Lösung
US5585108A (en) 1994-12-30 1996-12-17 Nanosystems L.L.C. Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays
US5466440A (en) 1994-12-30 1995-11-14 Eastman Kodak Company Formulations of oral gastrointestinal diagnostic X-ray contrast agents in combination with pharmaceutically acceptable clays
US5628981A (en) 1994-12-30 1997-05-13 Nano Systems L.L.C. Formulations of oral gastrointestinal diagnostic x-ray contrast agents and oral gastrointestinal therapeutic agents
US5560932A (en) 1995-01-10 1996-10-01 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents
US5662883A (en) 1995-01-10 1997-09-02 Nanosystems L.L.C. Microprecipitation of micro-nanoparticulate pharmaceutical agents
US5665331A (en) 1995-01-10 1997-09-09 Nanosystems L.L.C. Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers
US5569448A (en) 1995-01-24 1996-10-29 Nano Systems L.L.C. Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions
US5571536A (en) 1995-02-06 1996-11-05 Nano Systems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5560931A (en) 1995-02-14 1996-10-01 Nawosystems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5622938A (en) 1995-02-09 1997-04-22 Nano Systems L.L.C. Sugar base surfactant for nanocrystals
US5518738A (en) 1995-02-09 1996-05-21 Nanosystem L.L.C. Nanoparticulate nsaid compositions
US5593657A (en) 1995-02-09 1997-01-14 Nanosystems L.L.C. Barium salt formulations stabilized by non-ionic and anionic stabilizers
US5534270A (en) 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
US5500204A (en) 1995-02-10 1996-03-19 Eastman Kodak Company Nanoparticulate diagnostic dimers as x-ray contrast agents for blood pool and lymphatic system imaging
US5591456A (en) 1995-02-10 1997-01-07 Nanosystems L.L.C. Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer
US5573783A (en) 1995-02-13 1996-11-12 Nano Systems L.L.C. Redispersible nanoparticulate film matrices with protective overcoats
US5510118A (en) 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US5543133A (en) 1995-02-14 1996-08-06 Nanosystems L.L.C. Process of preparing x-ray contrast compositions containing nanoparticles
US5580579A (en) 1995-02-15 1996-12-03 Nano Systems L.L.C. Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
ATE274341T1 (de) 1995-02-24 2004-09-15 Elan Pharma Int Ltd Nanopartikel-dispersionen enthaltende aerosole
US5718919A (en) 1995-02-24 1998-02-17 Nanosystems L.L.C. Nanoparticles containing the R(-)enantiomer of ibuprofen
US5565188A (en) 1995-02-24 1996-10-15 Nanosystems L.L.C. Polyalkylene block copolymers as surface modifiers for nanoparticles
US5747001A (en) 1995-02-24 1998-05-05 Nanosystems, L.L.C. Aerosols containing beclomethazone nanoparticle dispersions
US5643552A (en) 1995-03-09 1997-07-01 Nanosystems L.L.C. Nanoparticulate diagnostic mixed carbonic anhydrides as x-ray contrast agents for blood pool and lymphatic system imaging
US5472683A (en) 1995-03-09 1995-12-05 Eastman Kodak Company Nanoparticulate diagnostic mixed carbamic anhydrides as X-ray contrast agents for blood pool and lymphatic system imaging
US5573749A (en) 1995-03-09 1996-11-12 Nano Systems L.L.C. Nanoparticulate diagnostic mixed carboxylic anhydrides as X-ray contrast agents for blood pool and lymphatic system imaging
US5521218A (en) 1995-05-15 1996-05-28 Nanosystems L.L.C. Nanoparticulate iodipamide derivatives for use as x-ray contrast agents
US5573750A (en) 1995-05-22 1996-11-12 Nanosystems L.L.C. Diagnostic imaging x-ray contrast agents
US5834025A (en) 1995-09-29 1998-11-10 Nanosystems L.L.C. Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions
FR2742357B1 (fr) 1995-12-19 1998-01-09 Rhone Poulenc Rorer Sa Nanoparticules stabilisees et filtrables dans des conditions steriles
RO120603B1 (ro) 1996-08-22 2006-05-30 Research Triangle Pharmaceuticals Ltd. Compoziţie conţinând microparticule de substanţe insolubile în apă şi procedeu de preparare
US6706690B2 (en) 1999-06-10 2004-03-16 Baxter Healthcare Corporation Hemoactive compositions and methods for their manufacture and use
US6039932A (en) 1996-09-27 2000-03-21 3M Innovative Properties Company Medicinal inhalation aerosol formulations containing budesonide
SE9604486D0 (sv) 1996-12-05 1996-12-05 Astra Ab Novel formulation
US6045829A (en) 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
WO1998035666A1 (en) 1997-02-13 1998-08-20 Nanosystems Llc Formulations of nanoparticle naproxen tablets
WO1998048847A1 (en) 1997-04-25 1998-11-05 Nycomed Imaging As Nanoparticle composition containing iodinated x-ray contrast agent as stabilizer for thermal sterilization
SE9701956D0 (sv) 1997-05-23 1997-05-23 Astra Ab New composition of matter
US6440455B1 (en) * 1997-09-02 2002-08-27 Children's Medical Center Corporation Methods for modulating the axonal outgrowth of central nervous system neurons
SE9704186D0 (sv) 1997-11-14 1997-11-14 Astra Ab New composition of matter
US6123923A (en) * 1997-12-18 2000-09-26 Imarx Pharmaceutical Corp. Optoacoustic contrast agents and methods for their use
US6066292A (en) 1997-12-19 2000-05-23 Bayer Corporation Sterilization process for pharmaceutical suspensions
US6512023B1 (en) * 1998-06-18 2003-01-28 Closure Medical Corporation Stabilized monomer adhesive compositions
US6153225A (en) 1998-08-13 2000-11-28 Elan Pharma International Limited Injectable formulations of nanoparticulate naproxen
US6165506A (en) 1998-09-04 2000-12-26 Elan Pharma International Ltd. Solid dose form of nanoparticulate naproxen
US8293277B2 (en) 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
IT1303692B1 (it) * 1998-11-03 2001-02-23 Chiesi Farma Spa Procedimento per la preparazione di sospensioni di particelle difarmaci da somministrare per inalazione.
US6428814B1 (en) * 1999-10-08 2002-08-06 Elan Pharma International Ltd. Bioadhesive nanoparticulate compositions having cationic surface stabilizers
US7521068B2 (en) 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
US6375986B1 (en) * 2000-09-21 2002-04-23 Elan Pharma International Ltd. Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6270806B1 (en) 1999-03-03 2001-08-07 Elan Pharma International Limited Use of peg-derivatized lipids as surface stabilizers for nanoparticulate compositions
US6267989B1 (en) 1999-03-08 2001-07-31 Klan Pharma International Ltd. Methods for preventing crystal growth and particle aggregation in nanoparticulate compositions
ATE271922T1 (de) 1999-06-01 2004-08-15 Elan Pharma Int Ltd Kleinmühle und verfahren dafür
EP1136080A3 (en) 2000-03-14 2002-06-05 Pfizer Products Inc. Use of o-vanillin and o-vanillin/trolox combinations
JP2003527210A (ja) 2000-03-23 2003-09-16 クリアラント・インコーポレイテッド 生体材料を滅菌するための方法
GB0009773D0 (en) 2000-04-19 2000-06-07 Univ Cardiff Particulate composition
US6316029B1 (en) 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
CA2412376A1 (en) 2000-07-26 2002-01-31 Onkar N. Singh Pharmaceutical suspension compositions lacking a polymeric suspending agent
GB0018528D0 (en) 2000-07-27 2000-09-13 Photocure Asa Compounds
US20030219461A1 (en) * 2000-09-12 2003-11-27 Britten Nancy J. Parenteral combination therapy for infective conditions
CA2449490C (en) 2001-06-05 2010-10-05 Elan Pharma International Limited System and method for milling materials
AU2002354913B2 (en) 2001-07-16 2008-07-17 Depuy Products, Inc. Unitary surgical device and method
PT1429731E (pt) 2001-09-19 2007-04-30 Elan Pharma Int Ltd Formulações de insulina nanoparticulada
US7112340B2 (en) * 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
ATE464880T1 (de) * 2002-02-04 2010-05-15 Elan Pharma Int Ltd Arzneistoffnanopartikel mit lysozym- oberflächenstabilisator
US20040105778A1 (en) * 2002-10-04 2004-06-03 Elan Pharma International Limited Gamma irradiation of solid nanoparticulate active agents
US7064187B2 (en) 2002-11-26 2006-06-20 Crosscart, Inc. Substantially non-immunogenic injectable collagen
EP1454636A1 (en) 2003-03-04 2004-09-08 Dompé S.P.A. Sterilization of glucocorticoid drug particles for pulmonary delivery

Similar Documents

Publication Publication Date Title
JP2007501683A5 (ja)
Wang et al. Advances in antimicrobial organic and inorganic nanocompounds in biomedicine
Ji et al. Antibacterial applications of graphene-based nanomaterials: recent achievements and challenges
Teng et al. Iodine Immobilized Metal–Organic Framework for NIR‐Triggered Antibacterial Therapy on Orthopedic Implants
de Miguel et al. Plasmon-based biofilm inhibition on surgical implants
Zhang et al. Light-activable on-demand release of nano-antibiotic platforms for precise synergy of thermochemotherapy on periodontitis
Osminkina et al. Porous silicon nanoparticles as scavengers of hazardous viruses
Butler et al. Review of antimicrobial nanocoatings in medicine and dentistry: mechanisms of action, biocompatibility performance, safety, and benefits compared to antibiotics
Welch et al. Dental adhesives with bioactive and on-demand bactericidal properties
Gambarini et al. In vitro evaluation of the cytotoxicity of FotoSan™ light-activated disinfection on human fibroblasts
Kasimanickam et al. Prevention and treatment of biofilms by hybrid-and nanotechnologies
JP5112669B2 (ja) 難溶性薬物のナノ微粒子を含有する水性懸濁液剤
Du et al. Evaluation of antibacterial effects by atmospheric pressure nonequilibrium plasmas against Enterococcus faecalis biofilms in vitro
WO2006108405A3 (de) Nanopartikel-wirkstoff-konjugate
NZ573555A (en) Nanoparticulate posaconazole formulations
NO20073289L (no) Nanopartikkelsammensetninger med kontrollert frigjoring som omfatter cephalosporin
N Oktar et al. Molecular mechanism and targets of the antimicrobial activity of metal nanoparticles
AR052033A1 (es) Composicion farmaceutica que comprende inhibidor de topoisomerasa i
CA2985171A1 (en) Aqueous suspension containing nanoparticles of glucocorticosteroid
TW200936145A (en) Functional nanoparticle-based antibiotics and preparation method thereof
CN107184982A (zh) 一种纳米光触媒消毒液及其制备方法
EP1868613A4 (en) POLYMORPHOS OF 3-O- (3 ', 3'-DIMETHYLSUCCINYL) BETULINIC DI-N-METHYL-D-GLUCAMINE
Mba et al. Application of nanotechnology in the treatment of infectious diseases: an overview
Sun et al. Ultrasound-driven radical chain reaction and immunoregulation of piezoelectric-based hybrid coating for treating implant infection
Ghazi et al. Evaluation of adding nanosized natural zeolite to photodynamic therapy against P. gingivalis biofilm on titanium disks